Document Detail


Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
MedLine Citation:
PMID:  18331610     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists such as thiazolidinediones (TZDs) improve insulin sensitivity in type 2 diabetes mellitus (T2DM) through effects on fat metabolism whereas GH stimulates lipolysis and induces insulin resistance. OBJECTIVE: To evaluate the impact of TZDs on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. DESIGN: A randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. INTERVENTION: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. RESULTS: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid (FFA) levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). CONCLUSION: The impact of GH on lipolysis and insulin sensitivity can be modified by administration of TZDs.
Authors:
Morten B Krag; Søren Nielsen; Zengkui Guo; Steen B Pedersen; Ole Schmitz; Jens S Christiansen; Jens O L Jørgensen
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2008-03-10
Journal Detail:
Title:  Clinical endocrinology     Volume:  69     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-10-17     Completed Date:  2009-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  452-61     Citation Subset:  IM    
Affiliation:
Medical Department M, Aarhus University Hospital, Aarhus Sygehus, Aarhus C, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / blood,  complications,  drug therapy*,  metabolism
Double-Blind Method
Growth Disorders / blood,  complications,  drug therapy*,  metabolism
Hormone Replacement Therapy
Human Growth Hormone / blood,  deficiency,  pharmacology*,  therapeutic use
Humans
Hypoglycemic Agents / administration & dosage,  pharmacology
Insulin / metabolism
Insulin Resistance*
Lipolysis / drug effects*
Male
Middle Aged
PPAR gamma / agonists*
Placebos
Thiazolidinediones / administration & dosage,  pharmacology*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Hypoglycemic Agents; 0/PPAR gamma; 0/Placebos; 0/Thiazolidinediones; 11061-68-0/Insulin; 111025-46-8/pioglitazone; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of race, body fat and season with vitamin D status among young women: a cross-sectional ...
Next Document:  Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?